Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205127966> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4205127966 abstract "Abstract Background: Ovarian cancer is initially responsive to frontline chemotherapy. Unfortunately, it often recurs and becomes resistant to available therapies and the survival rate for advanced and recurrent ovarian cancer is unacceptably low. We thus hypothesized that it would be possible to achieve more durable treatment responses by combining cisplatin chemotherapy with SW IV-134, a cancer-targeted peptide mimetic and inducer of cell death. SW IV-134 is a recently developed small molecule conjugate linking a sigma-2 ligand with a peptide analog (mimetic) of the intrinsic death pathway activator SMAC (second-mitochondria activator of caspases). The sigma-2 receptor is overexpressed in ovarian cancer and the sigma-2 ligand portion of the conjugate facilitates cancer selectivity. The effector portion of the conjugate is expected to synergize with cisplatin chemotherapy and the cancer selectivity is expected to reduce putative off-target toxicities. Methods: Ovarian cancer cell lines were treated with cisplatin alone, SW IV-134 alone and a combination of the two drugs. Treatment efficacy was determined using luminescent cell viability assays. Caspase-3/7,-8 and-9 activities were measured as complementary indicators of death pathway activation. Syngeneic mouse models and patient-derived xenograft (PDX) models of human ovarian cancer were studied for response to SW IV-134 and cisplatin monotherapy as well as combination therapy. Efficacy of the therapy was measured by tumor growth rate and survival as the primary readouts. Potential drug related toxicities were assessed at necropsy. Results: The combination treatment was consistently superior in multiple cell lines when compared to the single agents in vitro. The expected mechanism of tumor cell death, such as caspase activation, was confirmed using luminescent and flow cytometry-based assay systems. Combination therapy proved to be superior in both syngeneic and PDX-based murine models of ovarian cancer. Most notably, combination therapy resulted in a complete resolution of established tumors in all study animals in a patient-derived xenograft model of ovarian cancer. Conclusions: The addition of SW IV-134 in combination with cisplatin chemotherapy represents a promising treatment option that warrants further pre-clinical development and evaluation as a therapy for women with advanced ovarian cancer." @default.
- W4205127966 created "2022-01-26" @default.
- W4205127966 creator A5013020518 @default.
- W4205127966 creator A5046107872 @default.
- W4205127966 creator A5056113124 @default.
- W4205127966 creator A5060050760 @default.
- W4205127966 creator A5061406535 @default.
- W4205127966 creator A5076087889 @default.
- W4205127966 creator A5080722354 @default.
- W4205127966 creator A5088286796 @default.
- W4205127966 creator A5089554127 @default.
- W4205127966 creator A5002287278 @default.
- W4205127966 date "2022-01-12" @default.
- W4205127966 modified "2023-09-23" @default.
- W4205127966 title "The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancer" @default.
- W4205127966 doi "https://doi.org/10.21203/rs.3.rs-1153043/v1" @default.
- W4205127966 hasPublicationYear "2022" @default.
- W4205127966 type Work @default.
- W4205127966 citedByCount "0" @default.
- W4205127966 crossrefType "posted-content" @default.
- W4205127966 hasAuthorship W4205127966A5002287278 @default.
- W4205127966 hasAuthorship W4205127966A5013020518 @default.
- W4205127966 hasAuthorship W4205127966A5046107872 @default.
- W4205127966 hasAuthorship W4205127966A5056113124 @default.
- W4205127966 hasAuthorship W4205127966A5060050760 @default.
- W4205127966 hasAuthorship W4205127966A5061406535 @default.
- W4205127966 hasAuthorship W4205127966A5076087889 @default.
- W4205127966 hasAuthorship W4205127966A5080722354 @default.
- W4205127966 hasAuthorship W4205127966A5088286796 @default.
- W4205127966 hasAuthorship W4205127966A5089554127 @default.
- W4205127966 hasBestOaLocation W42051279661 @default.
- W4205127966 hasConcept C121608353 @default.
- W4205127966 hasConcept C126322002 @default.
- W4205127966 hasConcept C143998085 @default.
- W4205127966 hasConcept C170493617 @default.
- W4205127966 hasConcept C185592680 @default.
- W4205127966 hasConcept C190283241 @default.
- W4205127966 hasConcept C2776694085 @default.
- W4205127966 hasConcept C2778239845 @default.
- W4205127966 hasConcept C2780427987 @default.
- W4205127966 hasConcept C31573885 @default.
- W4205127966 hasConcept C502942594 @default.
- W4205127966 hasConcept C55493867 @default.
- W4205127966 hasConcept C71924100 @default.
- W4205127966 hasConcept C88045685 @default.
- W4205127966 hasConcept C96232424 @default.
- W4205127966 hasConcept C98274493 @default.
- W4205127966 hasConceptScore W4205127966C121608353 @default.
- W4205127966 hasConceptScore W4205127966C126322002 @default.
- W4205127966 hasConceptScore W4205127966C143998085 @default.
- W4205127966 hasConceptScore W4205127966C170493617 @default.
- W4205127966 hasConceptScore W4205127966C185592680 @default.
- W4205127966 hasConceptScore W4205127966C190283241 @default.
- W4205127966 hasConceptScore W4205127966C2776694085 @default.
- W4205127966 hasConceptScore W4205127966C2778239845 @default.
- W4205127966 hasConceptScore W4205127966C2780427987 @default.
- W4205127966 hasConceptScore W4205127966C31573885 @default.
- W4205127966 hasConceptScore W4205127966C502942594 @default.
- W4205127966 hasConceptScore W4205127966C55493867 @default.
- W4205127966 hasConceptScore W4205127966C71924100 @default.
- W4205127966 hasConceptScore W4205127966C88045685 @default.
- W4205127966 hasConceptScore W4205127966C96232424 @default.
- W4205127966 hasConceptScore W4205127966C98274493 @default.
- W4205127966 hasLocation W42051279661 @default.
- W4205127966 hasLocation W42051279662 @default.
- W4205127966 hasOpenAccess W4205127966 @default.
- W4205127966 hasPrimaryLocation W42051279661 @default.
- W4205127966 hasRelatedWork W1749117680 @default.
- W4205127966 hasRelatedWork W2053448942 @default.
- W4205127966 hasRelatedWork W2064215138 @default.
- W4205127966 hasRelatedWork W2068479722 @default.
- W4205127966 hasRelatedWork W2128816326 @default.
- W4205127966 hasRelatedWork W2170624001 @default.
- W4205127966 hasRelatedWork W2353260778 @default.
- W4205127966 hasRelatedWork W2370283463 @default.
- W4205127966 hasRelatedWork W2373869694 @default.
- W4205127966 hasRelatedWork W3215939181 @default.
- W4205127966 isParatext "false" @default.
- W4205127966 isRetracted "false" @default.
- W4205127966 workType "article" @default.